Showing 4771-4780 of 5623 results for "".
- Algorithm Compares Risk of Cancelled Ophthalmology Appointments Against COVID-19https://modernod.com/news/algorithm-compares-risk-of-cancelled-ophthalmology-appointments-against-covid-19/2478075/The COVID-19 pandemic has forced many ophthalmologists across the US to cancel potentially necessary eye examinations with patients since March. A team, led by Nikhil K. Bommakanti, MD, W.K. Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, developed a f
- Novartis Launches “Not Today, Dry Eye” Consumer Campaignhttps://modernod.com/news/novartis-launches-not-today-dry-eye-consumer-campaign/2478073/This month, Novartis launched its new direct-to-consumer commercial and campaign “Not Today, Dry Eye,” which aims to improve awareness of dry eye disease (DED) among consumers. This campaign underscores the fact that inflammation can play an important role in the development and amplification of
- Pepcid As a Coronavirus Remedy? Trump’s $21-Million Gamble Fizzledhttps://modernod.com/news/pepcid-as-a-coronavirus-remedy-trumps-21-million-gamble-fizzled/2478070/As the coronavirus began its deadly march through the world, two well-respected American doctors identified a possible but seemingly unlikely remedy: Pepcid, the heartburn medication found on drugstore shelves everywhere, according to an Associated
- Maculopathy Tied to Pentosan Polysulfate Sodium May Worsen After Drug Cessationhttps://modernod.com/news/maculopathy-tied-to-pentosan-polysulfate-sodium-may-worsen-after-drug-cessation/2478071/Pentosan polysulfate sodium (PPS)-associated maculopathy may continue for at least 10 years after drug cessation and in some cases may pose a threat to central vision, according to a case report, Reuters reported. The condition 
- Moderna Loses US Patent Challenge That Could Affect COVID-19 Vaccinehttps://modernod.com/news/moderna-loses-us-patent-challenge-that-could-affect-covid-19-vaccine/2478072/Shares in Moderna fell as much as 10% Thursday after the company failed in an attempt to invalidate a US patent on vaccine technology held by Arbutus Biopharma. SVB Leerink analyst Mani Foroohar suggested the decision by an administrative court run by the US Patent and Trademark Office opens the
- US to PayNearly $2 Billion for 100 Million Doses of Pfizer, BioNTech’s COVID-19 Vaccinehttps://modernod.com/news/us-to-paynearly-2-billion-for-100-million-doses-of-pfizer-biontechs-covid-19-vaccine/2478067/Pfizer and BioNTech announced that the US government agreed to pay $1.95 billion for an initial order of 100 million doses of BNT162, an mRNA-based COVID-19 vaccine candidate being jointly developed by the companies. Under the deal, the government can also acquire up to 500 million more doses.
- Aurinia Prices $200 Million Public Offering of Common Shareshttps://modernod.com/news/aurinia-prices-200-million-public-offering-of-common-shares/2478066/Aurinia Pharmaceuticals, a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, announced the pricing of its underwritten public offering of 13,333,334 common shares. The company is currently developing the investig
- MeiraGTx Announces Positive Clinical Data of Investigational Gene Therapy for X-Linked Retinitis Pigmentosahttps://modernod.com/news/meiragtx-announces-positive-clinical-data-of-investigational-gene-therapy-for-x-linked-retinitis-pigmentosa/2478062/MeiraGTx Holdings announced 6-month data from the ongoing phase 1/2 clinical trial of AAV-RPGR, an investigational gene therapy in development for the treatment of patients with X-linked retinitis pigmentosa (XLRP) with genetically confirmed variants in the RPGR gene. Significant improve
- Pfizer, BioNTech’s mRNA-Based COVID-19 Vaccine Shows Promise in Second Studyhttps://modernod.com/news/pfizer-biontechs-mrna-based-covid-19-vaccine-shows-promise-in-second-study/2478049/Pfizer and BioNTech announced that the most advanced of four COVID-19 vaccine candidates from their BNT162 mRNA-based vaccine program demonstrated the ability to elicit high SARS-CoV-2 neutralising titers after the second dose in an ongoing phase 1/2 study in Germany. The results, which were publ
- AffronEYE Saffron Extract Aims to Reduce Risks of Long-Term Blue-Light Induced Eye Injuryhttps://modernod.com/news/affroneye-saffron-extract-aims-to-reduce-risks-of-long-term-blue-light-induced-eye-injury/2478051/In a digital era, the increasing dependence on screens and technology particularly among gamers is prolonging exposure to blue light. Madrid, Spain-based nutraceutical company Pharmactive Biotech Products offers its proprietary affronEYE saffron ingredient, a fast